{"entity":{"id":"nct05903833","kind":"trial","name":"Pembrolizumab Combination With Lenvatinib in Pts With Recurrent,Persistent,Metastatic or Locally Advanced Vulvar Cancer Not Amenable to Curative Surge","aka":["PIERCE"],"tldr":"A phase 2 trial of Pembrolizumab, Lenvatinib in vulvar cancer, run by AGO Research GmbH, now recruiting.","summary":"Pembrolizumab Combination With Lenvatinib in Pts With Recurrent,Persistent,Metastatic or Locally Advanced Vulvar Cancer Not Amenable to Curative Surgery or Radiotherapy is a phase 2 interventional study registered as NCT05903833 by AGO Research GmbH, with 42 participants planned, started 2025-06-24 and due to reach its primary completion in 2027-10-30. Interventions recorded: Pembrolizumab, Lenvatinib. Conditions listed: Recurrent Vulvar Cancer, Persistent Vulvar Cancer, Metastatic Vulva Cancer, Locally Advanced Vulvar Cancer. No results are recorded here; the registry entry is the source.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT05903833","url":"https://clinicaltrials.gov/study/NCT05903833"}],"tags":["ctgov-ingest"],"related":[],"cancers":["vulvar","hpv-associated-vulvar-cancer","hpv-independent-vulvar-cancer"],"sections":[],"technologies":["antiangiogenic","checkpoint-inhibitor","kinase-inhibitors"],"targets":[],"drugs":["pembrolizumab","lenvatinib"],"companies":["ago-study-group"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT05903833","phase":"2","setting":"Pembrolizumab in Combination With Lenvatinib in Pts With Recurrent, Persistent, Metastatic or Locally Advanced Vulvar Cancer Not Amenable to Curative Surgery or Radiotherapy","sponsor":"AGO Research GmbH","started":"2025-06-24","startedType":"actual","enrolled":42,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct05903833/","neighbours":{"cancer":[{"id":"hpv-associated-vulvar-cancer","kind":"cancer","name":"HPV-associated vulvar squamous cell carcinoma","route":"/cancers/hpv-associated-vulvar-cancer/"},{"id":"hpv-independent-vulvar-cancer","kind":"cancer","name":"HPV-independent vulvar squamous cell carcinoma (p53-mutant)","route":"/cancers/hpv-independent-vulvar-cancer/"},{"id":"vulvar","kind":"cancer","name":"Vulvar cancer","route":"/cancers/vulvar/"}],"technology":[{"id":"antiangiogenic","kind":"technology","name":"Anti-angiogenic therapy","route":"/technologies/antiangiogenic/"},{"id":"checkpoint-inhibitor","kind":"technology","name":"Immune checkpoint inhibitors","route":"/technologies/checkpoint-inhibitor/"},{"id":"kinase-inhibitors","kind":"technology","name":"Small-molecule kinase inhibitors","route":"/technologies/kinase-inhibitors/"}],"drug":[{"id":"lenvatinib","kind":"drug","name":"Lenvatinib","route":"/drugs/lenvatinib/"},{"id":"pembrolizumab","kind":"drug","name":"Pembrolizumab","route":"/drugs/pembrolizumab/"}],"company":[{"id":"ago-study-group","kind":"company","name":"AGO Study Group","route":"/companies/ago-study-group/"}]}}